Finally, in FA patients, oxidative markers and/or antioxidant enzymes are also modified in response to frataxin depletion [17,51-54], which was found to be an incentive to trial antioxidant molecules in this disease [55-57]. The gene discussed is FXN; the disease is Friedreich ataxia.